Critical Therapeutics, Inc. Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 8 Calls Today's Calls

Call Details Critical Therapeutics, Inc. Earnings Conference Call (Q1 2008) Thu, May 8, 2008, 5:30 pm Eastern Listen to the archived event audio About Critical Therapeutics, Inc. (NasdaqGM:CRTX) Critical Therapeutics, Inc., a biopharmaceutical company, engages in developing and commercializing products to treat respiratory, inflammatory, and critical care diseases linked to body’s inflammatory response. It markets ZYFLO CR, a formulation of zileuton for the prevention and treatment of asthma in adults and children. The company also holds exclusive worldwide rights to ZYFLO CR; ZYFLO, an immediate-release tablet formulation of zileuton; and other formulations of zileuton for multiple diseases and conditions. In addition, Critical Therapeutics is developing zileuton injection, which is in Phase II clinical trial, for use in emergency room or urgent care centers for patients who suffer acute exacerbations of asthma. Further, it initiated a Phase I clinical trial to examine the pharmacokinetic and pharmacodynamic profile of the R(+) isomer of zileuton. Additionally, the company is conducting preclinical work in alpha-7 program for the development of a small molecule product candidate targeting the nicotinic alpha-7 cholinergic receptor, or alpha-7 receptor, for the treatment for severe acute inflammatory disease. It has an agreement with Dey, L.P. to promote ZYFLO and ZYFLO CR; and has a co-promotion agreement to promote DEY’s product PERFOROMIST for the treatment of chronic obstructive pulmonary disease. The company is also collaborating with MedImmune, Inc. on the development of monoclonal antibodies directed toward a cytokine called high mobility group box protein 1 (HMGB1); and Beckman Coulter, Inc. on the development of a diagnostic directed toward measuring HMGB1 in the bloodstream. Critical Therapeutics was founded in 2000. It was formerly known as Medicept, Inc. and changed its name to Critical Therapeutics, Inc. in 2001. The company is based in Lexington, Massachusetts. More Info: Quote | Chart | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings